Evidence map›Paper›PMID 37752574›Full record

ArticleParasites & vectors2023

First report of the efficacy of a fluralaner-based pour-on product (Exzolt® 5%) against ectoparasites infesting cattle in Brazil.

Alvimar José da Costa, João Ricardo de Souza Martins, Fernando de Almeida Borges, Luis Fernando Vettorato, Francisco Bonomi Barufi, Heitor de Oliveira Arriero Amaral, Luara Carolina Abujamra, Daniel de Castro Rodrigues, Welber Daniel Zanetti Lopes

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Management Practices for the Control ofPathogens (Basel, Switzerland) · 2026
    Review
  8. Review
  9. Does fluralaner (ExzoltParasites & vectors · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Alvimar José da CostaFaculdade de Ciências Agrárias e Veterinárias, Universidade Estadual Paulista, Jaboticabal, São Paulo, Brazil.ORCID http://orcid.org/0009-0007-7356-3989
João Ricardo de Souza MartinsInstituto de Pesquisas Desidério Finamor, Eldorado do Sul, Rio Grande do Sul, Brazil.ORCID http://orcid.org/0009-0002-0751-7128
Fernando de Almeida BorgesDepartamento de Medicina Veterinária, Universidade Federal do Mato Grosso Do Sul, Campo Grande, Mato Grosso do Sul, Brazil.ORCID http://orcid.org/0000-0002-8888-6269
Luis Fernando VettoratoMSD Saúde Animal, São Paulo, Brazil.ORCID http://orcid.org/0009-0001-3921-7296
Francisco Bonomi BarufiMSD Saúde Animal, São Paulo, Brazil.ORCID http://orcid.org/0009-0004-5685-5603
Heitor de Oliveira Arriero AmaralMSD Saúde Animal, São Paulo, Brazil.ORCID http://orcid.org/0009-0003-5260-7322
Luara Carolina AbujamraMSD Saúde Animal, São Paulo, Brazil.ORCID http://orcid.org/0009-0000-4748-5525
Daniel de Castro RodriguesMSD Saúde Animal, São Paulo, Brazil.ORCID http://orcid.org/0000-0001-9792-5744
Welber Daniel Zanetti LopesCentro de Parasitologia Veterinária, Universidade Federal de Goiás, Goiânia, Goiás, Brazil. wdzlopes@hotmail.com.ORCID http://orcid.org/0000-0002-8009-8436
Universidade Federal de Goiás · BRUniversidade Estadual Paulista (Unesp) · BRUniversidade Federal de Mato Grosso do Sul · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study describes the effectiveness of a novel active pharmaceutical ingredient, fluralaner (isoxazoline class), against important ectoparasites infesting cattle in Brazil.

methodsA total of 13 studies involving a 5% fluralaner-based pour-on formulation (Exzolt 5%; further referred to as Exzolt) were conducted. Specifically, the effectiveness of this formulation was studied against Rhipicephalus microplus (6 studies), Cochliomyia hominivorax larvae (4 studies), Dermatobia hominis larvae (1 study) and Haematobia irritans flies (2 studies).

resultsThe therapeutic efficacy of Exzolt was found to exceed 98% at 4 days post treatment (DPT), while persistent efficacy (> 90% efficacy) against repeated infestations of R. microplus was observed for up to 79 DPT. In field studies, ≥ 98% therapeutic efficacy was demonstrated at all study sites by 7 DPT, and a persistent efficacy (> 90% efficacy) was observed for 42, 49 or 56 DPT. Exzolt prevented C. hominivorax eggs from developing to the larval stage, thus mitigating the development of myiasis in cattle naturally and artificially infested with this screworm. The efficacy of Exzolt against D. hominis larvae was 98% at 3 DPT, while persistent efficacy (> 90% effectiveness) was found to last for up to 70 DPT. Against H. irritans, Exzolt showed therapeutic efficacy (≥ 90%) within the first day of treatment at both study sites, while persistent efficacy (≥ 90%) was observed for 7 DPT at one site and for 21 DPT at the other site.

conclusionsOverall, the results from these studies confirm that Exzolt is therapeutically efficacious against the most important ectoparasites infesting cattle in Brazil. The novel active pharmaceutical ingredient, fluralaner, provides a new treatment option for farmers to control cattle ectoparasites, especially where there is resistance to other chemical classes. In addition, an effective control of ectoparasites will improve overall cattle health and well-being as well as production.

Indexed as

Cattle DiseasesMuscidaeTick InfestationsAnimalsBrazilCattleDipteraIsoxazolesLarvaOvumPharmaceutical PreparationsA1443 compoundIsoxazolesPharmaceutical PreparationsCochliomyia hominivoraxDermatobia hominisFluralanerHaematobia irritansIsoxazolineRhipicephalus microplus

Identifiers

PMID37752574
PMCPMC10523720
OpenAlexW4387060732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.